fotemustine
Sign in to saveFotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. It is available in Europe but has not been approved by the United States FDA. A study has shown that fotemustine produces improved response rates but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, re
Research
415 papers- Fotemustine for the treatment of melanoma.Expert opinion on pharmacotherapy · 2011
- Fotemustine in the treatment of brain primary tumors and metastases.Cancer investigation · 1994
- Fotemustine in recurrent high‑grade glioma: MRI neuro‑radiological findings.Oncology letters · 2024
- An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.BioMed research international · 2014
- Focus on Fotemustine.Journal of experimental & clinical cancer research : CR · 2006
via PubMed
Wikidata facts
- Mass
- 315.075
Show 3 more facts
- chemical formula
- C₉H₁₉ClN₃O₅P
- canonical SMILES
- CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
- Commons category
- Fotemustine
Sources (2)
via Wikidata · CC0
~2 min read
Article
1 sectionsContents
- External links
{{Drugbox | Verifiedfields = changed | verifiedrevid = 461113915 | IUPAC_name = (RS)-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}ethyl)phosphonate | image = Fotemustine.svg | image_class = skin-invert-image | width = 200
| tradename = Mustophoran | Drugs.com = | pregnancy_AU = D | pregnancy_US = | pregnancy_category = | legal_AU = S4 | legal_UK = | legal_US = | legal_status = | routes_of_administration =
Available in 11 languages
via Wikidata sitelinks · CC0